世界のクリティカルケア診断市場は、2024年に14億5,000万米ドルと評価されており、2035年までには27億8,000万米ドルに達すると予想されており、予測期間（2024〜2035年）中に年平均成長率（CAGR）6.11％で拡大すると見込まれています。集中治療向け診断分野における進歩は、高度な重症患者環境での重要な意思決定を可能にする要素として注目されています。医療システムは、過去数年間で迅速かつ正確で、実用的な洞察を提供するために激しい競争を繰り広げてきました。敗血症、急性呼吸窮迫症候群（ARDS）、多臓器不全、重度外傷などの危険な状態は、診断技術が稼働する環境において、時間を「時間単位」ではなく「分単位」で扱う必要性を生じさせています。手術室、集中治療室（ICU）、救急部でのリアルタイムの生化学的、血液学的、免疫学的データの需要が高まるにつれて、臨床ワークフローに迅速に統合できるポイントオブケア（POC）検査ソリューションの需要も増加しています。
この変革は、患者数の増加や診断までのターンアラウンドタイムを短縮する必要性によってのみ影響されているわけではありません。診断までの時間短縮は、臨床医が生存率に大きな影響を与える介入を迅速に実施できる機会を生み出します。ますます多くの病院が、単純なルーチン化学分析から高度な免疫タンパク質プロファイリングまで、すべての検査機能を1つのコンパクトで高スループットのシステムに統合する診断プラットフォームに目を向けています。これにより、臨床検査のイノベーションと集中治療医学の融合が急速に進み、世界中の医療提供者の調達戦略を再形成しています。
また、主要医療機器グループによる研究投資の増加は、診断精度、追跡可能性、接続性に関して規制当局が設定する厳格な性能基準によって後押しされています。さらに、診断機器と電子カルテ（EHR）や病院情報システムとの相互運用性への注目が高まることで、技術の普及が加速しています。加えて、AIを活用した診断解釈により、敗血症、心血管不安定症、急性腎障害の早期特定における検査の予測価値が向上します。全体として、市場は、よりスマートで迅速かつ正確な診断エコシステムへのトレンドを採用し、集中治療医学の要件を満たす方向に進んでいます。
アボット・ラボラトリーズ、F. ホフマン・ラ・ロシュ、シーメンス・ヘルスケア、ダナハー、ビオメリュー、GEヘルスケア、サーモフィッシャーサイエンティフィック、Werfen Life Group、ノバ・バイオメディカル、Radiometer Medical ApS
目次
Chapter 1. Market Snapshot
1.1. Market Definition & Report Overview
1.2. Market Segmentation
1.3. Key Takeaways
1.3.1. Top Investment Pockets
1.3.2. Top Winning Strategies
1.3.3. Market Indicators Analysis
1.3.4. Top Impacting Factors
1.4. Application Ecosystem Analysis
1.4.1. 360’ Analysis
Chapter 2. Executive Summary
2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Market Attractiveness Analysis (top leader’s point of view on the market)
2.5. Key Findings
Chapter 3. Research Methodology
3.1. Research Objective
3.2. Supply Side Analysis
3.2.1. Primary Research
3.2.2. Secondary Research
3.3. Demand Side Analysis
3.3.1. Primary Research
3.3.2. Secondary Research
3.4. Forecasting Models
3.4.1. Assumptions
3.4.2. Forecasts Parameters
3.5. Competitive breakdown
3.5.1. Market Positioning
3.5.2. Competitive Strength
3.6. Scope of the Study
3.6.1. Research Assumption
3.6.2. Inclusion & Exclusion
3.6.3. Limitations
Chapter 4. Industry Landscape
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Porter’s 5 Forces Model
4.2.1. Bargaining Power of Buyer
4.2.2. Bargaining Power of Supplier
4.2.3. Threat of New Entrants
4.2.4. Threat of Substitutes
4.2.5. Competitive Rivalry
4.3. Value Chain Analysis
4.4. PESTEL Analysis
4.5. Pricing Analysis and Trends
4.6. Key growth factors and trends analysis
4.7. Market Share Analysis (2024)
4.8. Top Winning Strategies (2024)
4.9. Trade Data Analysis (Import Export)
4.10. Regulatory Guidelines
4.11. Historical Data Analysis
4.12. Analyst Recommendation & Conclusion
Chapter 5. Global Critical Care Diagnostics Market Size & Forecasts by Type 2024-2035
5.1. Market Overview
5.1.1. Market Size and Forecast By Type 2024-2035
5.2. Routine & Special Chemistry
5.2.1. Market definition, current market trends, growth factors, and opportunities
5.2.2. Market size analysis, by region, 2024-2035
5.2.3. Market share analysis, by country, 2024-2035
5.3. Flow Cytometry
5.3.1. Market definition, current market trends, growth factors, and opportunities
5.3.2. Market size analysis, by region, 2024-2035
5.3.3. Market share analysis, by country, 2024-2035
5.4. Hematology
5.4.1. Market definition, current market trends, growth factors, and opportunities
5.4.2. Market size analysis, by region, 2024-2035
5.4.3. Market share analysis, by country, 2024-2035
5.5. Immunoproteins
5.5.1. Market definition, current market trends, growth factors, and opportunities
5.5.2. Market size analysis, by region, 2024-2035
5.5.3. Market share analysis, by country, 2024-2035
Chapter 6. Global Critical Care Diagnostics Market Size & Forecasts by End Use 2024-2035
6.1. Market Overview
6.1.1. Market Size and Forecast By End Use 2024-2035
6.2. Operation Room
6.2.1. Market definition, current market trends, growth factors, and opportunities
6.2.2. Market size analysis, by region, 2024-2035
6.2.3. Market share analysis, by country, 2024-2035
6.3. Intensive Care Unit
6.3.1. Market definition, current market trends, growth factors, and opportunities
6.3.2. Market size analysis, by region, 2024-2035
6.3.3. Market share analysis, by country, 2024-2035
6.4. Emergency Rooms
6.4.1. Market definition, current market trends, growth factors, and opportunities
6.4.2. Market size analysis, by region, 2024-2035
6.4.3. Market share analysis, by country, 2024-2035
Chapter 7. Global Critical Care Diagnostics Market Size & Forecasts by Region 2024-2035
7.1. Regional Overview 2024-2035
7.2. Top Leading and Emerging Nations
7.3. North America Critical Care Diagnostics Market
7.3.1. U.S. Critical Care Diagnostics Market
7.3.1.1. Type breakdown size & forecasts, 2024-2035
7.3.1.2. End Use breakdown size & forecasts, 2024-2035
7.3.2. Canada Critical Care Diagnostics Market
7.3.2.1. Type breakdown size & forecasts, 2024-2035
7.3.2.2. End Use breakdown size & forecasts, 2024-2035
7.3.3. Mexico Critical Care Diagnostics Market
7.3.3.1. Type breakdown size & forecasts, 2024-2035
7.3.3.2. End Use breakdown size & forecasts, 2024-2035
7.4. Europe Critical Care Diagnostics Market
7.4.1. UK Critical Care Diagnostics Market
7.4.1.1. Type breakdown size & forecasts, 2024-2035
7.4.1.2. End Use breakdown size & forecasts, 2024-2035
7.4.2. Germany Critical Care Diagnostics Market
7.4.2.1. Type breakdown size & forecasts, 2024-2035
7.4.2.2. End Use breakdown size & forecasts, 2024-2035
7.4.3. France Critical Care Diagnostics Market
7.4.3.1. Type breakdown size & forecasts, 2024-2035
7.4.3.2. End Use breakdown size & forecasts, 2024-2035
7.4.4. Spain Critical Care Diagnostics Market
7.4.4.1. Type breakdown size & forecasts, 2024-2035
7.4.4.2. End Use breakdown size & forecasts, 2024-2035
7.4.5. Italy Critical Care Diagnostics Market
7.4.5.1. Type breakdown size & forecasts, 2024-2035
7.4.5.2. End Use breakdown size & forecasts, 2024-2035
7.4.6. Rest of Europe Critical Care Diagnostics Market
7.4.6.1. Type breakdown size & forecasts, 2024-2035
7.4.6.2. End Use breakdown size & forecasts, 2024-2035
7.5. Asia Pacific Critical Care Diagnostics Market
7.5.1. China Critical Care Diagnostics Market
7.5.1.1. Type breakdown size & forecasts, 2024-2035
7.5.1.2. End Use breakdown size & forecasts, 2024-2035
7.5.2. India Critical Care Diagnostics Market
7.5.2.1. Type breakdown size & forecasts, 2024-2035
7.5.2.2. End Use breakdown size & forecasts, 2024-2035
7.5.3. Japan Critical Care Diagnostics Market
7.5.3.1. Type breakdown size & forecasts, 2024-2035
7.5.3.2. End Use breakdown size & forecasts, 2024-2035
7.5.4. Australia Critical Care Diagnostics Market
7.5.4.1. Type breakdown size & forecasts, 2024-2035
7.5.4.2. End Use breakdown size & forecasts, 2024-2035
7.5.5. South Korea Critical Care Diagnostics Market
7.5.5.1. Type breakdown size & forecasts, 2024-2035
7.5.5.2. End Use breakdown size & forecasts, 2024-2035
7.5.6. Rest of APAC Critical Care Diagnostics Market
7.5.6.1. Type breakdown size & forecasts, 2024-2035
7.5.6.2. End Use breakdown size & forecasts, 2024-2035
7.6. LAMEA Critical Care Diagnostics Market
7.6.1. Brazil Critical Care Diagnostics Market
7.6.1.1. Type breakdown size & forecasts, 2024-2035
7.6.1.2. End Use breakdown size & forecasts, 2024-2035
7.6.2. Argentina Critical Care Diagnostics Market
7.6.2.1. Type breakdown size & forecasts, 2024-2035
7.6.2.2. End Use breakdown size & forecasts, 2024-2035
7.6.3. UAE Critical Care Diagnostics Market
7.6.3.1. Type breakdown size & forecasts, 2024-2035
7.6.3.2. End Use breakdown size & forecasts, 2024-2035
7.6.4. Saudi Arabia (KSA Critical Care Diagnostics Market
7.6.4.1. Type breakdown size & forecasts, 2024-2035
7.6.4.2. End Use breakdown size & forecasts, 2024-2035
7.6.5. Africa Critical Care Diagnostics Market
7.6.5.1. Type breakdown size & forecasts, 2024-2035
7.6.5.2. End Use breakdown size & forecasts, 2024-2035
7.6.6. Rest of LAMEA Critical Care Diagnostics Market
7.6.6.1. Type breakdown size & forecasts, 2024-2035
7.6.6.2. End Use breakdown size & forecasts, 2024-2035
Chapter 8. Company Profiles
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Abbott Laboratories
8.2.1.1. Company Overview
8.2.1.2. Key Executives
8.2.1.3. Company Snapshot
8.2.1.4. Financial Performance (Subject to Data Availability)
8.2.1.5. Product/Services Port
8.2.1.6. Recent Development
8.2.1.7. Market Strategies
8.2.1.8. SWOT Analysis
8.2.2. F. Hoffmann-La Roche Ltd
8.2.3. Siemens Healthineers AG
8.2.4. Danaher Corporation
8.2.5. bioMérieux SA
8.2.6. GE Healthcare
8.2.7. Thermo Fisher Scientific
8.2.8. Werfen Life Group
8.2.9. Nova Biomedical
8.2.10. Radiometer Medical ApS
